每经AI快讯,7月3日,中国生物制药(01177.HK)在港交所发布公告称,其开发的注射用重组人凝血因子VIIa N01已获上市批准,该药是国内首个获批上市的国产重组人凝血因子VIIa类生物制品。
特别声明:以上内容(如有图片或视频亦包括在内)为自媒体平台“网易号”用户上传并发布,本平台仅提供信息存储服务。
Notice: The content above (including the pictures and videos if any) is uploaded and posted by a user of NetEase Hao, which is a social media platform and only provides information storage services.